Javlor 25 mg/mL concentrate for solution for infusion
Sponsors
Janssen Cilag International, Gilead Sciences Inc.
Conditions
Advanced Urothelial CancerLocally Advanced or Metastatic Unresectable Urothelial Cancer
Phase 3
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab
in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Active, not recruitingCTIS2023-510296-56-00
Start: 2018-03-26Target: 179Updated: 2025-08-26
Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
CompletedCTIS2024-513870-23-00
Start: 2021-06-28End: 2025-05-21Target: 391Updated: 2025-05-13